The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna (MRNA – Research Report), with a price target ...

Akero Therapeutics stock doubled Monday, pulling shares of rival 89bio higher, after the biotech company's treatment for a ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.